Publication: Relationship of body mass index with efficacy of exenatide twice daily added to insulin glargine in patients with type 2 diabetes
| dc.contributor.author | Wolffenbuttel, B. H. R. | |
| dc.contributor.author | Van Gaal, L. | |
| dc.contributor.author | Duran-Garcia, S. | |
| dc.contributor.author | Han, J. | |
| dc.contributor.authoraffiliation | [Wolffenbuttel, B. H. R.] Univ Groningen, Univ Med Ctr Groningen, Dept Endocrinol, HPC AA31, NL-9700 RB Groningen, Netherlands | |
| dc.contributor.authoraffiliation | [Van Gaal, L.] Univ Antwerp Hosp, Dept Endocrinol Diabetol & Metab, Antwerp, Belgium | |
| dc.contributor.authoraffiliation | [Duran-Garcia, S.] Hosp Univ Virgen Valme, Unidad Gest Endocrinol & Nutr, Seville, Spain | |
| dc.contributor.authoraffiliation | [Han, J.] Pharmapace Inc, San Diego, CA USA | |
| dc.contributor.funder | alliance of Eli Lilly and Company | |
| dc.contributor.funder | Amylin Pharmaceuticals | |
| dc.contributor.funder | alliance of Bristol-Myers Squibb | |
| dc.contributor.funder | AstraZeneca | |
| dc.date.accessioned | 2023-02-12T02:21:32Z | |
| dc.date.available | 2023-02-12T02:21:32Z | |
| dc.date.issued | 2016-08-01 | |
| dc.description.abstract | This post hoc analysis assessed the evidence behind common reimbursement practices by evaluating the relationship of body mass index (BMI) ranges (35 kg/m(2)) with treatment effects of exenatide twice daily among patients with type 2 diabetes. Patients received exenatide twice daily added to insulin glargine in two 30-week studies (exenatide twice daily vs insulin lispro, n = 627; exenatide twice daily vs placebo, n = 259). No association of baseline BMI with changes in efficacy variables was observed. Glycated haemoglobin (HbA1c) reductions were significant (p | |
| dc.identifier.doi | 10.1111/dom.12669 | |
| dc.identifier.essn | 1463-1326 | |
| dc.identifier.issn | 1462-8902 | |
| dc.identifier.unpaywallURL | https://doi.org/10.1111/dom.12669 | |
| dc.identifier.uri | http://hdl.handle.net/10668/18985 | |
| dc.identifier.wosID | 379904300011 | |
| dc.issue.number | 8 | |
| dc.journal.title | Diabetes obesity & metabolism | |
| dc.journal.titleabbreviation | Diabetes obes. metab. | |
| dc.language.iso | en | |
| dc.organization | Área de Gestión Sanitaria Sur de Sevilla | |
| dc.organization | AGS - Sur de Sevilla | |
| dc.page.number | 829-833 | |
| dc.publisher | Wiley | |
| dc.rights | Attribution-NonCommercial 4.0 International | |
| dc.rights.accessRights | open access | |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ | |
| dc.subject | body mass index | |
| dc.subject | exenatide twice daily | |
| dc.subject | type 2 diabetes | |
| dc.subject | Peptide-1 receptor agonist | |
| dc.subject | Basal insulin | |
| dc.subject | Bolus insulin | |
| dc.subject | Safety | |
| dc.subject | Liraglutide | |
| dc.subject | Management | |
| dc.subject | Degludec | |
| dc.title | Relationship of body mass index with efficacy of exenatide twice daily added to insulin glargine in patients with type 2 diabetes | |
| dc.type | research article | |
| dc.type.hasVersion | VoR | |
| dc.volume.number | 18 | |
| dc.wostype | Article | |
| dspace.entity.type | Publication |